All News

A new study suggests that incorporating proteomic data can help refine risk stratification in mantle cell lymphoma (MCL).

Zanubrutinib had low discontinuation and atrial fibrillation rates in R/R CLL/SLL, supporting tolerability over first-generation BTK inhibitors.

Learn how CRS and ICANS present in patients undergoing immunotherapy and what clinicians should know about recognizing and managing these toxicities.

Mammography use fell significantly among younger, uninsured, and non-Hispanic White and Asian women from 2002-2022, with the 2009 USPSTF guideline change a likely driver.

Continuing conversations from last year, experts at the AAD Annual Meeting in Denver weighed the pros and cons of teledermatology and AI.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The FDA's March 2026 approvals marked significant regulatory milestones across multiple disease states.

Attempts to refine non–small cell lung cancer treatment selection have been limited by a lack of biomarkers, but recent research is expanding the potential landscape.

Adults can undergo CAR T-cell therapy for relapsed or refractory mantle cell lymphoma after the full approval of the treatment.

A global cohort has tracked pediatric HIV growth after dolutegravir, showing early catch-up weight gain, then stable BMI without long-term obesity risk.

Evaluation of more than 65,000 trials and 350,000 investigator sites highlights significant exposure in oncology and late-stage development.

Chronic skin diseases are increasingly being understood as systemic conditions driven by the interconnected brain-gut-skin axis.

FDA approves Eli Lilly's orforglipron (Foundayo), the first GLP-1 obesity pill with no food or water restrictions.

The FDA now permits outpatient monitoring for epcoritamab’s first full dose in R/R DLBCL, as EPCORE-NHL-6 data support safe bispecific antibody access.

New real-world data highlight sustained response and remission rates with esketamine nasal spray for patients with treatment-resistant depression.

Novo Nordisk launches a Wegovy subscription program to reduce costs, expand access, and improve long-term adherence.

Dual inhibition of BIRC5 and MCL-1 showed strong synergistic activity in preclinical models of MCL.

A machine learning model using routine clinical data more accurately predicted 5-year heart failure risk in patients with CKD than traditional tools.

Lower actual wearable use was found in patients with multiple sclerosis (MS) despite comparable intentions to use the wearable technology.

Low serum IgE levels were independently associated with nearly double the risk of developing CLL in a retrospective cohort study of 118,740 adults.

Half of working-age Medicaid enrollees face disenrollment under national work requirements, despite having greater functional impairment than those who would comply.

Soficabtagene geleucel is the first CAR T-cell therapy designed specifically to target T-cell malignancies.

There were few incidences of complications in the follow-up period after the MicroShunt was implanted in the patient.

TrumpRx launched in early February with the aim to offer lower-priced drugs to those without insurance or those who would like to pay in cash. The results are more complicated.

Education and personal factors influence willingness more than physician recommendation alone, a new study found.

The study, evaluating the efficacy of the combination of efgartigimod alfa and hyaluronidase-qvfc, is the first to specifically evaluate those with ocular myasthenia gravis.

Insulin icodec-abae (Awiqli; Novo Nordisk) is now approved for use in the US, Canada, European Union, Switzerland, and 12 other countries.

Combining traditional dermatopathology with PCR-based molecular testing improves diagnostic accuracy in differentiating eczema from psoriasis, particularly in ambiguous cases.